Business Intelligence on Biologic and Small Molecule Drugs
Figure 4 – The distribution of the actives identified from the registered compounds
Figure 4. The distribution of the 1800 confirmed actives identified from the nearly 50,000 registered compounds represents an approximate 4% confirmed hit rate over all projects and reflects Lilly's internal research priorities.